Alumis Presents Detailed Positive Phase 3 Data for Envudeucitinib in Psoriasis, Reinforcing Strong Efficacy and Safety

summarizeSummary

Alumis Inc. filed an 8-K to announce the presentation of detailed positive Phase 3 clinical trial results for envudeucitinib in plaque psoriasis at the 2026 American Academy of Dermatology Annual Meeting, confirming robust efficacy and a favorable safety profile.

check_boxKey Events

• Detailed Phase 3 Results Presented

  Alumis presented comprehensive 24-week data from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis at the 2026 American Academy of Dermatology Annual Meeting.

• Robust Efficacy Confirmed

  Envudeucitinib achieved high thresholds of clinical response, with 68.0% and 62.1% of patients reaching PASI 90, and 41.0% and 39.5% achieving PASI 100 by Week 24 in the respective trials. Early onset of action and sustained improvements were observed.

• Significant Quality of Life Improvements

  The trials demonstrated early and deepening improvements in quality of life (DLQI-0/1 in ~50% of patients by Week 12) and itch relief, often preceding significant skin clearance.

• Favorable Safety Profile

  Envudeucitinib showed a generally well-tolerated safety profile consistent with previous Phase 2 studies, with no new safety signals, low rates of serious adverse events, and no clinically significant laboratory abnormalities.

auto_awesomeAnalysis

This 8-K provides the detailed clinical data from the Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, following the initial topline announcement on March 19, 2026. The presentation of robust efficacy and a favorable safety profile at a major medical conference (AAD) solidifies the drug's potential as a leading oral therapy. The specific data points, such as high PASI 90 and PASI 100 response rates and improvements in quality of life, provide critical validation for investors and strengthen the company's position as it prepares for an NDA submission in the second half of 2026. This detailed disclosure confirms the strong positive sentiment surrounding the drug's development.